Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HLA-DRB1 | P01911 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.31 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | CASP9 | P55211 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22479788 | 0.89 | BACE1 (0.32) | HLA-DRB1ELANEMEN1KMT2A | |
| SCHEMBL22519648 | 0.89 | BACE1 (0.32) | HLA-DRB1ELANEMEN1KMT2A | |
| SCHEMBL29375589 | 0.89 | BACE1 (0.32) | HLA-DRB1ELANEMEN1KMT2A | |
| SCHEMBL22463088 | 0.88 | ERAP2 (0.32) | BRD4NPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL22463092 | 0.88 | ERAP2 (0.32) | BRD4NPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL29330374 | 0.87 | BRD4 (0.32) | HTTBRD4SMN1; SMN2NPSR1MEN1 | |
| SCHEMBL24320587 | 0.86 | HLA-DRB1 (0.36) | HLA-DRB1BRD4SMN1; SMN2ELANE | |
| SCHEMBL22463100 | 0.79 | AAK1 (0.30) | — | |
| SCHEMBL22463099 | 0.79 | AAK1 (0.30) | — | |
| SCHEMBL22479920 | 0.76 | ELANE (0.32) | ELANEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795225-B2 | Therapeutic binding molecules | MEDIMMUNE LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-20220098308-A1 | THERAPEUTIC BINDING MOLECULES | MEDIMMUNE LIMITED (GB) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795225-B2 | Therapeutic binding molecules | EPCAM, IGSF11, FCGR3B | HLA-DRB1 172/4885HTT 3039/4885BRD4 691/4885 |
| US-20220098308-A1 | THERAPEUTIC BINDING MOLECULES | EPCAM, IGSF11, FCGR3B | HLA-DRB1 172/4885HTT 3039/4885BRD4 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.